|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Strong associations with CBC were found for carrying a BRCA1 (RR = 3.7; 95%CI:2.8-4.9), BRCA2 (RR = 2.8; 95%CI:1.8-4.3) or CHEK2 c.1100delC (RR = 2.7; 95%CI:2.0-3.7) mutation.
|
30580169 |
2019 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thus, we conducted a prospective study of the relationship between oophorectomy and the risk of contralateral breast cancer in 1781 BRCA1 and 503 BRCA2 mutation carriers with breast cancer.
|
30756284 |
2019 |
|
Contralateral breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
There were no significant differences in disease-free survival, overall survival, or breast cancer-specific survival (p = 0.799, 0.092, and 0.124, respectively) between BRCA 1/2 carriers and non-carriers, although BRCA 1/2 carriers showed significantly worse contralateral breast cancer-free survival (p < 0.0001) than non-carriers.
|
30350268 |
2019 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In the multivariable model, BRCA1/2 germline mutation status, family history, and systemic adjuvant treatment showed the strongest associations with CBC risk.
|
31847907 |
2019 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The incidence rate of contralateral breast cancer in BRCA1/2 mutation carriers was 0.99%/year.
|
29176636 |
2018 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Purpose The Women's Environmental Cancer and Radiation Epidemiology (WECARE) study demonstrated the importance of breast cancer family history on contralateral breast cancer (CBC) risk, even for noncarriers of deleterious BRCA1/2 mutations.
|
29620998 |
2018 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Notably, women with ER-/PR- first tumors were more likely to develop CBC with the ER-/PR- phenotype (RR = 5.4, 95% CI 3.0-9.5), and risk remained elevated in multiple subgroups: BRCA1/2 mutation non-carriers, women younger than 45 years of age, women without a breast cancer family history, and women who were not treated with tamoxifen.
|
28724391 |
2017 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Contralateral prophylactic mastectomy (CPM) reduces the risk of contralateral breast cancer (BC) following unilateral BC, but may not increase survival in BRCA1/2 mutation negative women.
|
27969575 |
2017 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRCA1 carriers and non-carriers developed contralateral breast cancer at an earlier age than BRCA2 carriers.
|
27726213 |
2017 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
For contralateral breast cancer, the cumulative risk 20 years after breast cancer diagnosis was 40% (95% CI, 35%-45%) for BRCA1 and 26% (95% CI, 20%-33%) for BRCA2 carriers (hazard ratio [HR] for comparing BRCA2 vs BRCA1, 0.62; 95% CI, 0.47-0.82; P=.001 for difference).
|
28632866 |
2017 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Moreover, contralateral prophylactic mastectomy (CPM) significantly decreased contralateral breast cancer incidence in BRCA1/2 mutation carriers (RR, 0.072; 95% CI, 0.035-0.148).
|
26979395 |
2016 |
|
Contralateral breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Women diagnosed with breast cancer who carry pathogenic variants in genes with proven associations with breast cancer (BRCA1/2) or highly likely associations (PTEN, PALB2) require additional risk assessment to facilitate treatment decisions that will limit in-breast tumor recurrence and contralateral breast cancer.
|
27401444 |
2016 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Age at first breast cancer is a strong risk factor for cumulative CBC risk in BRCA1/2 mutation carriers.
|
26700119 |
2016 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis.
|
26239694 |
2015 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age.
|
26467044 |
2015 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRCA1/2 mutation status was predictive of contralateral breast cancer only.
|
26113392 |
2015 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
It can reasonably be offered to breast cancer patients with BRCA1 or BRCA2 mutation for the prevention of CBC.
|
26022977 |
2015 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Female breast cancer patients with a BRCA1/2 mutation have an increased risk of contralateral breast cancer.
|
24423928 |
2014 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The cumulative 5-years risk of CBC for BRCA1 and BRCA2 mutation carriers was 15% (95% CI: 9.5%-20%) and 9% (95% CI: 5%-14%), respectively.
|
25467311 |
2014 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
|
24951267 |
2014 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The average cumulative risks by age 70 years for BRCA1 carriers were estimated to be 60% (95% confidence interval [CI] = 44% to 75%) for breast cancer, 59% (95% CI = 43% to 76%) for ovarian cancer, and 83% (95% CI = 69% to 94%) for contralateral breast cancer.
|
23628597 |
2013 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: Implications for counseling.
|
23165859 |
2013 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Contralateral breast cancer risk in BRCA1/2-positive families needs to be adjusted for phenocopy rates particularly in second-degree untested relatives.
|
23448362 |
2013 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We examined whether the risk of CBC associated with radiation treatment was higher among women with germline BRCA1/BRCA2 mutations than among non-carriers.
|
23706288 |
2013 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRCA1 or BRCA2 mutation carriers more accurately perceived their risk for contralateral breast cancer, whereas women without a known mutation substantially overestimated this risk.
|
24042365 |
2013 |